Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 4, 2010, Pages 383-388

  Sanjak, Mohammed ^a   Salachas, Francois ^b   Frija Orvoen, Elizabeth ^c   Theys, Paul ^d   Hutchinson, Duncan ^e   Verheijde, Joseph ^f   Pianta, Thomas ^g   Stewart, Heather ^h   Brooks, Benjamin Rix ^a   Meininger, Vincent ^b   Douillet, Patrice ⁱ  

^a Department of Neurology   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Service Pneumologie   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MAYO CLINIC   (United States)

^g Delmarva Foundation for Medical Care   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ SANOFI   (France)

Author keywords

Outcome measures; Quality control; Reliability; S clinical trial

Indexed keywords

PLACEBO; RILUZOLE; XALIPRODEN;

ACCURACY; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GOLD STANDARD; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; VITAL CAPACITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; STANDARDS; STATISTICS; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 77953792515     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960903486083     Document Type: Article

References (19)

1. Brooks BR, Sufit RL, Depaul R, Tan YD, Sanjak M, Robbins J. Design of clinical therapeutic trials in ALS. In: Munsat TL, editor. Advances in Neurology: Amyotrophic Lateral Sclerosis. New York: Butterworth; 1991. pp. 521-546
2. Munsat TL. Issues in amyotrophic lateral sclerosis clinical trial design. Adv Neurol. 1995;68:209-218
3. World Federation of Neurology (WFN) Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House Guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House 'Therapeutic Trials in ALS' Workshop Contributors. J Neurol Sci. 1995;129:1-10.
4. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research. J Neurol Sci. 1999;169:2-12.
5. Brinkman J, Andres P, Mendoza M, Sanjak M. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J Neurol Sci. 1997;147:97-111.
6. Enright PL, Johnson LR, Connett JE, Voelker H, Buist AS. Spirometry in the Lung Health Study. Am Rev Respir Dis. 1991;143:1215-1223
7. Malmstrom K, Peszek I, Botto A, Lu S, Enright PL, Reiss TF Botto A. Quality assurance of asthma clinical trials. Control Clin Trials. 2002;23:143-156
8. Pellegrino R, Decramer M, van Schayck CP, Dekhuijzen PN, Troosters T, van Herwaarden C, et al. Quality control of spirometry: a lesson from the BRONCUS trial. Eur Respir J. 2005;26:1104-1109
9. Meininger V, Bensimon G, Bradley WR, Brooks B, Douillet P, Eisen AA, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:107-117
10. American Thoracic Society Statement. Snowbird Workshop on Standardization of Spirometery. Am Rev Respir Dis. 1979;119:831-838
11. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volume and forced ventilatory flows. Report of Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J. 1993;6(Suppl 6):5-40.
12. Standardization of Spirometery. Update Respir Care. 1987;32:1039-1051
13. Cook RD. Detection of influential observations in linear regression. Technometrics. 1977;19:15-18
14. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46: 1244.
15. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. . Effect of recombinant human insulin-like growth factor-1 on progression of ALS: a placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology. 1997;49:1621-1630
16. Bradley WG, Miller RG, and the BDNF Study Group (phase III). Phase III trial of subcutaneous recombinant human BDNF in patients with amyotrophic lateral sclerosis. Neurology. 1999;52:1427-1433
17. Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al. A randomized, placebocontrolled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456-464
18. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain. 2001;124:2000-2013
19. Meininger V, Bensimon G, Lacomblez L, Salachas F. Natural history of amyotrophic lateral sclerosis. In: Serratrice G, Munsat T, editors. Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis, Advances in Neurology, vol.28. Philadelphia: Lippincott-Raven Publishers; 1995. pp. 199-207.